Can Abbott’s connected neuromodulation platforms improve life for chronic pain and movement disorder patients? episode artwork

EPISODE · Mar 31, 2026 · 44 MIN

Can Abbott’s connected neuromodulation platforms improve life for chronic pain and movement disorder patients?

from DeviceTalks Podcast Network · host DeviceTalks Podcast Network

In the final episode of AbbottTalks season 3, hosts Tom Salemi and Kayleen Brown sit down with Rebecca Wilkins, divisional vice president of R&D for Abbott’s Neuromodulation business, to discuss the technologies Abbott is advancing for chronic pain and movement disorders.Wilkins explains how Abbott’s spinal cord stimulation platforms, Proclaim™ DRG Neurostimulation System, and Infinity™ deep brain stimulation system are designed to interrupt errant nervous system signals, helping patients manage conditions ranging from chronic pain and Parkinson’s disease to, potentially, treatment-resistant depression.The conversation also highlights the features shaping Abbott’s neuromodulation portfolio, including Bluetooth-enabled connectivity, the NeuroSphere™ Virtual Clinic for remote programming, improved MRI compatibility including prone MRI access, and device options that balance small size with low recharge demands.Wilkins also shares new data presented at NANS showing significant reductions in pain-related healthcare encounters for patients using Abbott’s spinal cord stimulation and DRG therapies. This episode is brought to you by Confluent Medical Technologies. To learn more about Confluent, visit: https://confluentmedical.com/. Make sure to catch Confluent's March DeviceTalks Tuesdays webinar highlighting its new technology, Filmcast Select™: https://event.on24.com/wcc/r/5241831/7E70E13249532E05CA8FB3D51421AD71?partnerref=confluent *** Enjoy this podcast? Follow AbbottTalks on all major podcast players: https://abbotttalks.castos.com/ Subscribe + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe Chapters (00:00:00) - Intro: Reflecting on Season 3(00:05:22) - (Part 1) Interview with Confluent Medical's Brittany Mai(00:07:56) - Keynote Interview: Rebecca Wilkins, DVP of R&D at Abbott’s neuromodulation business(00:13:57) - A Personal Connection: How DBS Impacted a Family(00:16:21) - Innovation in Connectivity: Bluetooth and NeuroSphere™ Virtual Clinic(00:21:37) - (Part 2) Interview with Confluent Medical's Brittany Mai(00:24:42) - Targeted Therapy: Understanding Spinal Cord and DRG Stimulation(00:32:37) - Breaking Barriers: MRI Compatibility and Device Longevity(00:36:04) - New Data from NANS: Validating Patient Outcomes

Episode metadata supplied by the publisher feed · Published Mar 31, 2026

Embed this episode

NOW PLAYING

Can Abbott’s connected neuromodulation platforms improve life for chronic pain and movement disorder patients?

0:00 44:53

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of DeviceTalks Podcast Network?

This episode is 44 minutes long.

When was this DeviceTalks Podcast Network episode published?

This episode was published on March 31, 2026.

Can I download this DeviceTalks Podcast Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!